UnitedHealth Group has traditionally traded at a valuation premium to its peers, reflecting its diversified business mix and consistent earnings growth. Over the past year, however, the stock’s total return of approximately –10% has trailed the broader healthcare insurers group, which gained roughly 5% over the same period. Investors are scrutinizing whether UnitedHealth’s near 22× forward price-to-earnings ratio remains justified given rising competitive pressures in Medicare Advantage, potential regulatory headwinds around pharmacy benefit management, and decelerating revenue growth expectations from 12% year-over-year to an anticipated 8% in fiscal 2026.

Third-quarter Form 13F filings show that Lee Financial Co established a new position of 3,390 shares valued at $1.17 million, while Brighton Jones LLC more than doubled its stake, adding 28,231 shares to reach 44,249 shares worth $22.38 million. Revolve Wealth Partners LLC also increased its holding by 137%, acquiring 2,324 additional shares for a total position of 4,019 shares valued at $2.03 million. Despite these inflows, roughly 88% of the company’s float remains held by hedge funds and institutional investors, underscoring continued confidence in its long-term growth runway.

Wall Street sentiment remains moderately positive: among 29 tracked brokerages, one maintains a strong-buy recommendation, 17 suggest buy, nine have hold ratings and two recommend sell, resulting in an average consensus of Moderate Buy. Price targets span from $327 to $430, with an unweighted mean of $376.75. Notably, Jefferies lowered its target from $418 to $340 while upholding a buy stance, and Oppenheimer trimmed its objective to $385 but retained an outperform view. The divergence in targets highlights divergent views on the company’s ability to sustain mid-teens EPS growth under evolving reimbursement dynamics.

In the quarter ended January 27, UnitedHealth delivered $2.11 earnings per share, surpassing consensus by $0.02, on revenue of $113.22 billion, just shy of the $113.38 billion forecast. Year-over-year revenue growth of 12.3% reflected strength in both the benefits and Optum segments, while net margin held at 2.7% and return on equity came in at 14.8%. The company reaffirmed guidance for full-year adjusted EPS of $17.75. On the capital return front, the board declared a quarterly dividend of $2.21 per share, representing an annualized yield near 3.1% and a payout ratio of 67%.